Continuous subcutaneous apomorphine infusion in the early phase of advanced Parkinson's disease: A prospective study of 22 patients.
Advanced Parkinson’s disease
Apomorphine infusion
Device-aided therapies
Frontal dysfunction
Non-motor symptoms
Journal
Clinical parkinsonism & related disorders
ISSN: 2590-1125
Titre abrégé: Clin Park Relat Disord
Pays: England
ID NLM: 101761473
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
10
2021
revised:
30
11
2021
accepted:
13
12
2021
entrez:
10
1
2022
pubmed:
11
1
2022
medline:
11
1
2022
Statut:
epublish
Résumé
Parkinson's disease (PD) patients usually start treatment with apomorphine infusion (APO) in later stages of advanced PD (aPD). This timing limits the evaluation of its motor efficacy and other potential clinical benefits throughout the full course of aPD. We prospectively analyzed the effect of APO on motor and non-motor symptoms, cognitive function and quality of life (QoL) in 22 PD patients with early stage aPD, defined as: age < 71 years and diagnosis of aPD for < 3 years. At baseline, mean (±SD) age and disease duration were 59.4 ± 6.1 and 8.7 ± 3.5 years, respectively. After 6 months of APO treatment, daily In patients with early stage initial aPD, s substantial benefit of APO was observed on motor symptoms, driven by a 70% reduction in
Identifiants
pubmed: 35005605
doi: 10.1016/j.prdoa.2021.100129
pii: S2590-1125(21)00041-4
pmc: PMC8718975
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100129Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Parkinsons Dis. 2020;10(s1):S65-S73
pubmed: 32651333
J Neurol. 2016 Jun;263(6):1111-9
pubmed: 27060084
J Neurol. 2019 Mar;266(3):659-666
pubmed: 30617907
N Engl J Med. 2013 Feb 14;368(7):610-22
pubmed: 23406026
Lancet Neurol. 2015 May;14(5):518-31
pubmed: 25895932
J Neurol. 2017 May;264(5):946-954
pubmed: 28364292
J Neurol Sci. 2018 Dec 15;395:113-118
pubmed: 30312901
J Pharmacol Exp Ther. 2002 Nov;303(2):791-804
pubmed: 12388666
Mov Disord. 2005 Feb;20(2):151-7
pubmed: 15390035
Parkinsonism Relat Disord. 2012 Jan;18(1):40-4
pubmed: 21890396
Front Behav Neurosci. 2011 Oct 24;5:71
pubmed: 22028687
Mov Disord. 2014 Dec;29(14):1796-801
pubmed: 25370724
Mov Disord. 2019 Mar;34(3):353-365
pubmed: 30719763
Parkinsonism Relat Disord. 2017 Dec;45:33-38
pubmed: 29032012
J Neurol Sci. 2017 Jan 15;372:279-287
pubmed: 28017228
Ann Neurol. 2005 Jan;57(1):17-26
pubmed: 15514976
Mov Disord. 2015 Apr;30(4):510-6
pubmed: 25382161
Neuroscience. 2014 Dec 12;282:248-57
pubmed: 25445194
Parkinsonism Relat Disord. 2016 Dec;33 Suppl 1:S36-S41
pubmed: 27939326
J Parkinsons Dis. 2016 Oct 19;6(4):787-792
pubmed: 27662329
Front Cell Neurosci. 2017 Feb 08;11:27
pubmed: 28228718
J Parkinsons Dis. 2011;1(2):197-203
pubmed: 23934921
Parkinsonism Relat Disord. 2021 Feb;83:79-85
pubmed: 33486139
Trends Neurosci. 2009 Oct;32(10):517-24
pubmed: 19758714
Lancet Neurol. 2018 Sep;17(9):749-759
pubmed: 30055903
Parkinsonism Relat Disord. 2016 Feb;23:17-22
pubmed: 26709292
Parkinsonism Relat Disord. 2010 Jan;16(1):71-2
pubmed: 19524477
Mov Disord. 2008 Jun 15;23(8):1130-6
pubmed: 18442107
Mov Disord. 2002 Nov;17(6):1235-41
pubmed: 12465062